Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) CEO Joseph Truitt sold 133,484 shares of the business’s stock in a transaction dated Wednesday, October 16th. The shares were sold at an average price of $6.37, for a total value of $850,293.08. Following the completion of the sale, the chief executive officer now directly owns 103,734 shares of the company’s stock, valued at $660,785.58. The sale was disclosed in a legal filing with the SEC, which is available through this link.
ACHN traded down $0.11 during midday trading on Friday, reaching $6.09. 6,386,438 shares of the company were exchanged, compared to its average volume of 1,961,746. The company’s fifty day moving average price is $4.01 and its 200 day moving average price is $3.45. The company has a market cap of $509.88 million, a price-to-earnings ratio of -11.94 and a beta of 1.57. Achillion Pharmaceuticals, Inc. has a one year low of $1.29 and a one year high of $6.44.
Achillion Pharmaceuticals (NASDAQ:ACHN) last issued its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported ($0.14) EPS for the quarter, hitting analysts’ consensus estimates of ($0.14). On average, sell-side analysts forecast that Achillion Pharmaceuticals, Inc. will post -0.59 EPS for the current year.
A number of institutional investors and hedge funds have recently modified their holdings of ACHN. MetLife Investment Advisors LLC bought a new stake in Achillion Pharmaceuticals during the 1st quarter worth approximately $200,000. Metropolitan Life Insurance Co NY bought a new stake in Achillion Pharmaceuticals during the 1st quarter worth approximately $131,000. SG Americas Securities LLC bought a new stake in Achillion Pharmaceuticals during the 2nd quarter worth approximately $97,000. DekaBank Deutsche Girozentrale increased its holdings in Achillion Pharmaceuticals by 63.8% during the 2nd quarter. DekaBank Deutsche Girozentrale now owns 108,600 shares of the biopharmaceutical company’s stock worth $289,000 after purchasing an additional 42,300 shares in the last quarter. Finally, Swiss National Bank increased its holdings in Achillion Pharmaceuticals by 21.3% during the 2nd quarter. Swiss National Bank now owns 245,100 shares of the biopharmaceutical company’s stock worth $657,000 after purchasing an additional 43,000 shares in the last quarter. 78.57% of the stock is owned by hedge funds and other institutional investors.
Achillion Pharmaceuticals Company Profile
Achillion Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small molecule drug therapies for immune system disorders. Its lead drug candidate is ACH-4471, an inhibitor of factor D that is Phase II clinical trials for patients with paroxysmal nocturnal hemoglobinuria (PNH) and C3 glomerulopathy/immune complex membranoproliferative glomerulonephritis.
Receive News & Ratings for Achillion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achillion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.